drugset / Trial / NCT00849472
Treatment With Pazopanib for Neoadjuvant Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
Timeline
- Start
- 2009-07
- Primary completion
- 2011-12
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | 800 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |